US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
AU2004200325B2
(en)
*
|
1998-10-21 |
2006-09-28 |
Shire Llc |
Oral Pulsed Dose Drug Delivery System
|
US20010055613A1
(en)
*
|
1998-10-21 |
2001-12-27 |
Beth A. Burnside |
Oral pulsed dose drug delivery system
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US20080102121A1
(en)
*
|
1998-11-02 |
2008-05-01 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
|
ID29852A
(id)
*
|
1998-11-02 |
2001-10-18 |
Elan Corp Plc Cs |
Komposisi pelepasan modifikasi multi partikulasi
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US7083808B2
(en)
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
WO2000056362A2
(en)
*
|
1999-03-24 |
2000-09-28 |
The Secretary Of State For Defence |
Polycationic carbohydrates as immunostimulants in vaccines
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
AU764453B2
(en)
|
1999-10-29 |
2003-08-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US6500462B1
(en)
*
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
EP1248594B1
(de)
*
|
2000-01-19 |
2005-12-14 |
Mannkind Corporation |
Formulierung mit mehrfach gepulster wirkstofffreisetzung
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US20050181063A1
(en)
*
|
2000-03-22 |
2005-08-18 |
Alpar Hazire O. |
Pharmaceutical composition for administration to mucosal surfaces
|
US20020132001A1
(en)
*
|
2000-05-11 |
2002-09-19 |
Garthwaite Susan M. |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US6500457B1
(en)
*
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
WO2002017918A2
(en)
*
|
2000-08-30 |
2002-03-07 |
Pfizer Products Inc. |
Sustained release formulations for growth hormone secretagogues
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6344215B1
(en)
*
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
CN101317825A
(zh)
|
2000-10-30 |
2008-12-10 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
IT1319655B1
(it)
|
2000-11-15 |
2003-10-23 |
Eurand Int |
Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
|
IL155959A0
(en)
|
2000-11-28 |
2003-12-23 |
Fmc Corp |
Edible pga (propylene glycol alginate) coating composition
|
WO2002064654A1
(fr)
*
|
2001-02-09 |
2002-08-22 |
Reika Kogyo Kabushiki Kaisha |
Particule fonctionnelle, procede de preparation de celle-ci et procede de traitement par plasma
|
JP5005157B2
(ja)
*
|
2001-03-13 |
2012-08-22 |
ペンウェスト ファーマシューティカルズ カンパニー |
時間治療(chronotherapeutic)投与形態
|
NZ529308A
(en)
*
|
2001-04-05 |
2005-03-24 |
Collagenex Pharm Inc |
Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
|
WO2003004031A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
US20040142013A1
(en)
*
|
2001-07-13 |
2004-07-22 |
Flow Focusing, Inc. |
Implantable orthopedic surgical devices with controlled release antimicrobial component
|
WO2003005996A1
(en)
*
|
2001-07-13 |
2003-01-23 |
Flow Focusing, Inc. |
Programmable controlled release injectable opioid formulation
|
US20070254009A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic/bone morphogenic protein formulation and method of treatment
|
US20060263401A1
(en)
*
|
2001-07-13 |
2006-11-23 |
Flow Focusing, Inc. |
Formulation and Method for Preventing Infection
|
US20030055075A1
(en)
*
|
2001-07-13 |
2003-03-20 |
Rubsamen Reid M. |
Programmable controlled release injectable opioid formulation
|
US20070254008A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic formulation and method of treatment
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
*
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
IS7142A
(is)
|
2001-08-06 |
2004-02-05 |
Euroceltique S.A. |
Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
EP1429730A4
(de)
*
|
2001-09-26 |
2010-06-16 |
Penwest Pharmaceuticals Compan |
Opioid-formulierungen mit verringertem missbrauchspotenzial
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
AUPR839001A0
(en)
*
|
2001-10-19 |
2001-11-15 |
Eli Lilly And Company |
Dosage form, device and methods of treatment
|
PL374310A1
(en)
*
|
2001-12-11 |
2005-10-03 |
University Of Virginia Patent Foundation |
Use of pramipexole to treat amyotrophic lateral sclerosis
|
US20060281797A1
(en)
*
|
2001-12-11 |
2006-12-14 |
University Of Virginia Patent Foundation |
Neurorestoration with R(+) Pramipexole
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
WO2003074029A1
(en)
*
|
2002-03-07 |
2003-09-12 |
Vectura Limited |
Fast melt multiparticulate formulations for oral delivery
|
CA2480824A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
PT1492511E
(pt)
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
US7053034B2
(en)
*
|
2002-04-10 |
2006-05-30 |
Salvona, Llc |
Targeted controlled delivery compositions activated by changes in pH or salt concentration
|
CA2395819A1
(en)
*
|
2002-08-13 |
2004-02-13 |
Bernard Charles Sherman |
Dual-spike release formulation for oral drug delivery
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
WO2004034959A2
(en)
*
|
2002-09-18 |
2004-04-29 |
Elan Corporation, Plc |
Multiparticulate modified release composition comprising beraprost
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US20050191244A1
(en)
*
|
2002-10-25 |
2005-09-01 |
Gruenenthal Gmbh |
Abuse-resistant pharmaceutical dosage form
|
MXPA05004648A
(es)
*
|
2002-10-30 |
2005-06-08 |
Pharmacia Corp |
Comprimidos orales de liberacion extendida y procedimientos de preparacion y uso de los mismos.
|
US20050038042A1
(en)
*
|
2002-11-15 |
2005-02-17 |
Jenet Codd |
Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
|
GB0228571D0
(en)
|
2002-12-06 |
2003-01-15 |
Novartis Ag |
Organic compounds
|
US7988993B2
(en)
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
EP2959893A1
(de)
|
2002-12-13 |
2015-12-30 |
DURECT Corporation |
Orales arzneimittelverabreichungssystem mit hochviskosen flüssigkeitsträgermaterialien
|
US20040224020A1
(en)
*
|
2002-12-18 |
2004-11-11 |
Schoenhard Grant L. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
AU2003303631B2
(en)
*
|
2002-12-26 |
2008-05-29 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company |
Multilayer Dosage Forms Containing NSAIDs and Triptans
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7153526B2
(en)
*
|
2003-02-26 |
2006-12-26 |
Frank Steven R |
Treatment of gastrointestinal infections
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
US20050137265A1
(en)
*
|
2003-03-31 |
2005-06-23 |
Haley Eugene T. |
Rapidly dissolving metoclopramide solid oral dosage and method thereof
|
US20040192781A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Haley Eugene T. |
Method of administration for metoclopramide and pharmaceutical formulation therefor
|
MXPA05010636A
(es)
*
|
2003-04-04 |
2005-12-12 |
Pharmacia Corp |
Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
|
DK1615622T3
(da)
|
2003-04-07 |
2012-10-15 |
Supernus Pharmaceuticals Inc |
Doxycyclinpræparater til indgivelse én gang dagligt
|
WO2004100929A1
(en)
|
2003-05-12 |
2004-11-25 |
Synergia Pharma, Inc. |
Threo-dops controlled release formulation
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
AU2004258944B2
(en)
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
CA2533178C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
EP1653925A1
(de)
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Robustes pellet
|
JP2007502294A
(ja)
|
2003-08-12 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
WO2005016317A1
(en)
*
|
2003-08-19 |
2005-02-24 |
Themis Laboratories Private Limited |
Process for manufacture of extended release pellets containing diltiazem hci
|
WO2005023184A2
(en)
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
US7790201B2
(en)
*
|
2003-09-03 |
2010-09-07 |
Mallinckrodt Inc. |
Granular sustained release preparation and production thereof
|
CA2538064C
(en)
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
US7906125B2
(en)
*
|
2003-09-18 |
2011-03-15 |
Boston Scientific Scimed, Inc. |
Solid or semi-solid therapeutic formulations
|
MXPA06003101A
(es)
*
|
2003-09-19 |
2006-06-20 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
WO2005027878A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Penwest Pharmaceuticals Co. |
Delayed released dosage forms
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US20050220873A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
US8461187B2
(en)
|
2004-06-16 |
2013-06-11 |
Takeda Pharmaceuticals U.S.A., Inc. |
Multiple PPI dosage form
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
EP1771158A4
(de)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
Tablette für pulsierte abgabe
|
EP2036546B1
(de)
*
|
2004-08-23 |
2018-10-10 |
PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG |
Psychostimulantium mit einer pharmazeutischen Zusammensetzung
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US9149472B2
(en)
|
2004-08-31 |
2015-10-06 |
Jack William Schultz |
Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
GB0421121D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Natrocell Technologies Ltd |
Composite rodenticide
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
WO2006036969A2
(en)
|
2004-09-28 |
2006-04-06 |
Atrium Medical Corporation |
Formation of barrier layer
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
WO2006036982A2
(en)
|
2004-09-28 |
2006-04-06 |
Atrium Medical Corporation |
Drug delivery coating for use with a stent
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
US20060078621A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Wedinger Robert S |
Method of providing customized drug delivery systems
|
NZ728442A
(en)
|
2004-10-21 |
2018-05-25 |
Adare Pharmaceuticals Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
AR051654A1
(es)
*
|
2004-11-04 |
2007-01-31 |
Astrazeneca Ab |
Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
|
AR052225A1
(es)
*
|
2004-11-04 |
2007-03-07 |
Astrazeneca Ab |
Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
EP2623095A1
(de)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injizierbare Olanzapin-Formulierungen in Nanoteilchenform
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
EP1830648A4
(de)
*
|
2004-12-09 |
2008-03-12 |
Celgene Corp |
Behandlung mit d-threo-methylphenidat
|
WO2006066063A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Elan Pharma International Ltd. |
Nanoparticulate tacrolimus formulations
|
US20060269596A1
(en)
*
|
2005-01-12 |
2006-11-30 |
Gary Liversidge |
Controlled release compositions comprising an acylanilide
|
MX2007008985A
(es)
*
|
2005-01-26 |
2007-12-06 |
Elan Pharma Int Ltd |
Composiciones de liberacion controlada que comprenden un agente anti-sicotico.
|
GB0501809D0
(en)
*
|
2005-01-28 |
2005-03-09 |
Pharmakodex Ltd |
Anti-migraine formulations
|
CA2598410A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
CA2598288A1
(en)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of heterocyclic amide derivatives
|
WO2006102964A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Evonik Röhm Gmbh |
Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
|
CA2603084A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
DE112006000873T5
(de)
*
|
2005-04-12 |
2008-03-06 |
Elan Pharma International Ltd. |
Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs
|
EA200702221A1
(ru)
*
|
2005-04-12 |
2008-04-28 |
Элан Фарма Интернэшнл Лимитед |
Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
|
US20090252807A1
(en)
*
|
2005-04-13 |
2009-10-08 |
Elan Pharma International Limited |
Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
JP2009514989A
(ja)
*
|
2005-05-10 |
2009-04-09 |
エラン コーポレーション ピーエルシー |
改変放出ロキソプロフェン組成物
|
AU2006344711A1
(en)
*
|
2005-05-16 |
2008-01-24 |
Alkermes Pharma Ireland Limited |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
KR20080047509A
(ko)
*
|
2005-05-23 |
2008-05-29 |
엘란 파마 인터내셔널 리미티드 |
혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
|
JP2009517485A
(ja)
|
2005-06-08 |
2009-04-30 |
エラン・ファルマ・インターナショナル・リミテッド |
セフジトレンを含むナノ粒子状および制御放出組成物
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
JP2009516636A
(ja)
*
|
2005-06-13 |
2009-04-23 |
エラン コーポレーション ピーエルシー |
改変放出チクロピジン組成物
|
AU2006259224B2
(en)
|
2005-06-16 |
2012-08-23 |
Mohammed Saeed |
Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
|
EA200800092A1
(ru)
*
|
2005-06-20 |
2008-06-30 |
Элан Фарма Интернэшнл Лимитед |
Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
|
NZ561375A
(en)
|
2005-06-27 |
2011-06-30 |
Biovail Lab Int Srl |
Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
|
JP5059759B2
(ja)
*
|
2005-07-28 |
2012-10-31 |
ユニバーシティ オブ ハル |
スポロポレニンを含有する外皮またはそのフラグメントの使用方法
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
ES2334061T3
(es)
*
|
2005-08-15 |
2010-03-04 |
University Of Virginia Patent Foundation |
Neurorrestauracion con pramipexol r(+).
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
FR2891459B1
(fr)
*
|
2005-09-30 |
2007-12-28 |
Flamel Technologies Sa |
Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
|
JP2009511607A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
|
EP1954257A4
(de)
*
|
2005-10-14 |
2009-05-20 |
Lundbeck & Co As H |
Verfahren zur behandlung von erkrankungen des zentralen nervensystems mit einer niedrigdosierten kombination aus escitalopram und bupropion
|
AU2006304590A1
(en)
|
2005-10-15 |
2007-04-26 |
Atrium Medical Corporation |
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
|
US20070098791A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
|
US20070098796A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
|
MX2008006888A
(es)
*
|
2005-11-28 |
2008-09-30 |
Marinus Pharmaceuticals |
Formulas y metodos para la manufactura y uso de la ganaxolona.
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US20070134322A1
(en)
*
|
2005-12-14 |
2007-06-14 |
Forest Laboratories, Inc. |
Modified and pulsatile release pharmaceutical formulations of escitalopram
|
US20070141147A1
(en)
*
|
2005-12-21 |
2007-06-21 |
Auriga Laboratories, Inc. |
Sequential release pharmaceutical formulations
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
CN103211779B
(zh)
*
|
2006-01-27 |
2016-03-16 |
阿代尔制药股份有限公司 |
包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
|
CA2640382C
(en)
*
|
2006-01-27 |
2015-12-29 |
Eurand, Inc |
Drug delivery systems comprising weakly basic drugs and organic acids
|
KR100753480B1
(ko)
*
|
2006-01-27 |
2007-08-31 |
씨제이 주식회사 |
잘토프로펜 함유 서방성 정제 및 그 제조방법
|
KR100762847B1
(ko)
*
|
2006-01-27 |
2007-10-04 |
씨제이 주식회사 |
멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
|
WO2007095092A2
(en)
|
2006-02-09 |
2007-08-23 |
Alba Therapeutics Corporation |
Formulations for a tight junction effector
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
KR20070091960A
(ko)
*
|
2006-03-08 |
2007-09-12 |
주식회사종근당 |
졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
|
RU2435569C2
(ru)
|
2006-03-16 |
2011-12-10 |
Трис Фарма, Инк. |
Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
|
WO2007112581A1
(en)
*
|
2006-04-03 |
2007-10-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
US8518926B2
(en)
*
|
2006-04-10 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Compositions and methods of using (R)-pramipexole
|
US20070253927A1
(en)
*
|
2006-04-13 |
2007-11-01 |
Gwenaelle Jegou |
Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
|
US20070243250A1
(en)
*
|
2006-04-17 |
2007-10-18 |
Actavis Group Ptc Hf |
Oral Dosage Formulations and Methods of Preparing the Same
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
WO2007136663A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Flow Focusing, Inc. |
Antibiotic/bone morphogenic protein formulation and method of treatment
|
ATE537826T1
(de)
|
2006-05-16 |
2012-01-15 |
Knopp Neurosciences Inc |
Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
WO2007150074A2
(en)
*
|
2006-06-23 |
2007-12-27 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
CA2660650A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
|
EP2043623A4
(de)
*
|
2006-07-12 |
2013-03-20 |
Elan Pharma Int Ltd |
Nanopartikelformulierungen von modafinil
|
EP2049087A2
(de)
*
|
2006-07-21 |
2009-04-22 |
LAB International SRL |
Hydrophiles missbrauchssicheres ausgabesystem
|
US8889184B2
(en)
*
|
2006-09-07 |
2014-11-18 |
Losan Pharma Gmbh |
Particulate form of a pharmaceutical composition which is easy to swallow
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
WO2008027993A2
(en)
|
2006-08-31 |
2008-03-06 |
Eurand, Inc. |
Drug delivery systems comprising solid solutions of weakly basic drugs
|
US20080064694A1
(en)
*
|
2006-09-11 |
2008-03-13 |
Auriga Laboratories, Inc. |
Multi-Phase Release Methscopolamine Compositions
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
WO2008033155A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Auriga Laboratories, Inc. |
Kits for prevention and treatment of rhinitis
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20080085312A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Auriga Laboratories, Inc. |
Multi-Phase Release Potassium Guaiacolsulfonate Compositions
|
US20090069247A1
(en)
*
|
2006-10-06 |
2009-03-12 |
Blake Paterson |
Use of tight junction antagonists to treat inflammatory bowel disease
|
JP2010522135A
(ja)
|
2006-10-09 |
2010-07-01 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
WO2008052185A2
(en)
|
2006-10-26 |
2008-05-02 |
Alba Therapeutics Corp |
Materials and methods for the treatment of celiac disease
|
US20110212175A1
(en)
*
|
2006-10-30 |
2011-09-01 |
Hanall Biopharma Co., Ltd. |
Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
|
KR100985254B1
(ko)
*
|
2006-10-30 |
2010-10-04 |
한올바이오파마주식회사 |
방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와HMG―CoA 환원 효소 억제제의 복합 조성물
|
US8394845B2
(en)
*
|
2006-10-30 |
2013-03-12 |
Hanall Biopharma Co., Ltd. |
Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
WO2008057328A2
(en)
|
2006-11-06 |
2008-05-15 |
Atrium Medical Corporation |
Tissue separating device with reinforced support for anchoring mechanisms
|
EP2394643B1
(de)
|
2006-11-17 |
2015-09-02 |
Supernus Pharmaceuticals, Inc. |
Topiramat-Formulierungen mit verzögerter Freisetzung
|
WO2008064192A2
(en)
*
|
2006-11-21 |
2008-05-29 |
Mcneil-Ppc, Inc. |
Modified release analgesic suspensions
|
EP2101735A2
(de)
*
|
2006-11-28 |
2009-09-23 |
Marinus Pharmaceuticals, Inc. |
Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
|
CN102114002B
(zh)
*
|
2006-12-04 |
2016-05-11 |
苏佩努斯制药公司 |
托吡酯的增强的立即释放制剂
|
US8524695B2
(en)
*
|
2006-12-14 |
2013-09-03 |
Knopp Neurosciences, Inc. |
Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
|
WO2008102264A2
(en)
|
2007-02-20 |
2008-08-28 |
Eurand Pharmaceuticals Limited |
Stable digestive enzyme compositions
|
US20080227805A1
(en)
*
|
2007-02-28 |
2008-09-18 |
Abbott Laboratories |
Sustained release parenteral formulations of buprenorphine
|
US8519148B2
(en)
|
2007-03-14 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Synthesis of chirally purified substituted benzothiazole diamines
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20080318994A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20090060983A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
AU2008318851B2
(en)
*
|
2007-10-31 |
2014-04-17 |
Mcneil-Ppc, Inc. |
Orally disintegrated dosage form
|
WO2009088414A2
(en)
|
2007-12-06 |
2009-07-16 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
WO2009085306A1
(en)
|
2007-12-28 |
2009-07-09 |
Impax Laboratories, Inc. |
Controlled release formulations of levodopa and uses thereof
|
JP5714910B2
(ja)
|
2008-01-09 |
2015-05-07 |
チャールストン ラボラトリーズ,インコーポレイテッド |
薬学的組成物
|
US20100137442A2
(en)
*
|
2008-02-01 |
2010-06-03 |
Xenoport, Inc. |
Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
|
US10087493B2
(en)
|
2008-03-07 |
2018-10-02 |
Aptalis Pharma Canada Ulc |
Method for detecting infectious parvovirus in pharmaceutical preparations
|
US8372432B2
(en)
*
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
AU2009223061B2
(en)
*
|
2008-03-11 |
2014-10-09 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8133506B2
(en)
*
|
2008-03-12 |
2012-03-13 |
Aptalis Pharmatech, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
CA2627198A1
(en)
*
|
2008-03-27 |
2009-09-27 |
Pharmascience Inc. |
Methylphenidate extended release therapeutic drug delivery system
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
GB0812513D0
(en)
*
|
2008-07-09 |
2008-08-13 |
Univ Hull |
Delivery vehicle
|
US20110190356A1
(en)
*
|
2008-08-19 |
2011-08-04 |
Knopp Neurosciences Inc. |
Compositions and Methods of Using (R)- Pramipexole
|
DE102008048729A1
(de)
*
|
2008-09-24 |
2010-03-25 |
Add Technologies Ltd Advanced Drug Delivery |
Multipartikuläre Tabletten und Verfahren zur deren Herstellung
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
EP2368546A4
(de)
*
|
2008-11-07 |
2013-11-20 |
Samyang Biopharmaceuticals |
Pharmazeutische zusammensetzung für die gesteuerte freisetzung von methylphenidat
|
CN102245171A
(zh)
*
|
2008-11-10 |
2011-11-16 |
株式会社爱茉莉太平洋 |
缓释微粒及其制备方法
|
US8551517B2
(en)
*
|
2008-12-16 |
2013-10-08 |
Kimberly-Clark Worldwide, Inc. |
Substrates providing multiple releases of active agents
|
WO2010078486A2
(en)
|
2008-12-31 |
2010-07-08 |
Upsher-Smith Laboratories, Inc. |
Opioid-containing oral pharmaceutical compositions and methods
|
CA2752233C
(en)
|
2009-02-13 |
2017-01-03 |
Romark Laboratories L.C. |
Controlled release pharmaceutical formulations of nitazoxanide
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
RU2589823C2
(ru)
*
|
2009-04-09 |
2016-07-10 |
Алкермес Фарма Айэленд Лимитед |
Композиция для доставки лекарственных средств
|
EA201101530A1
(ru)
*
|
2009-04-21 |
2012-03-30 |
Селекта Байосайенсиз, Инк. |
ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
|
EP2421530B1
(de)
*
|
2009-04-24 |
2019-08-21 |
Iceutica Pty Ltd. |
Metaxalonformulierung
|
EP2435092A2
(de)
|
2009-05-27 |
2012-04-04 |
Selecta Biosciences, Inc. |
Nanoträger mit komponenten mit verschiedenen freisetzungsraten
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
KR20120059582A
(ko)
*
|
2009-08-31 |
2012-06-08 |
데포메드 인코퍼레이티드 |
아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
|
BR112012008317A2
(pt)
|
2009-09-17 |
2016-03-22 |
Upsher Smith Lab Inc |
produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
|
US20110070286A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Andreas Hugerth |
Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
|
US20110318411A1
(en)
|
2010-06-24 |
2011-12-29 |
Luber Joseph R |
Multi-layered orally disintegrating tablet and the manufacture thereof
|
US8313768B2
(en)
|
2009-09-24 |
2012-11-20 |
Mcneil-Ppc, Inc. |
Manufacture of tablet having immediate release region and sustained release region
|
US20110070301A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Luber Joseph R |
Orally transformable tablets
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
MX2012006240A
(es)
|
2009-12-02 |
2012-10-03 |
Aptalis Pharma Ltd |
Microcapsulas de fexofenadina y composiciones que contienen las mismas.
|
RU2554087C2
(ru)
|
2009-12-18 |
2015-06-27 |
Айденикс Фармасьютикалз, Инк. |
5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
US9993793B2
(en)
|
2010-04-28 |
2018-06-12 |
The Procter & Gamble Company |
Delivery particles
|
US9186642B2
(en)
|
2010-04-28 |
2015-11-17 |
The Procter & Gamble Company |
Delivery particle
|
CA2798702A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholresistant metoprolol-containing extended-release oral dosage forms
|
WO2011146583A2
(en)
|
2010-05-19 |
2011-11-24 |
Elan Pharma International Limited |
Nanoparticulate cinacalcet formulations
|
ES2661978T3
(es)
|
2010-05-26 |
2018-04-04 |
Selecta Biosciences, Inc. |
Vacunas multivalentes de nanovehículos sintéticos
|
CA2801930A1
(en)
*
|
2010-06-16 |
2011-12-22 |
Takeda Pharmaceuticals U.S.A., Inc. |
Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
|
WO2012009707A2
(en)
|
2010-07-16 |
2012-01-19 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
ES2581840T3
(es)
|
2010-09-01 |
2016-09-07 |
Ambit Biosciences Corporation |
Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
|
CN101933913A
(zh)
*
|
2010-09-16 |
2011-01-05 |
孙卫东 |
一种盐酸右哌甲酯双释放制剂及其制备方法
|
WO2012040710A2
(en)
*
|
2010-09-24 |
2012-03-29 |
Case Western Reserve University |
Stabilized nanobubbles for diagnostic and therapeutic applications
|
CL2011002432A1
(es)
|
2010-10-01 |
2012-04-20 |
Aptalis Pharma Ltd |
Composicion que comprende al menos una enzima digestiva y al menos un portador, en donde el portador comprende celulosa microcristalina que tiene un tamaño de particulas mayor que 100 um; una forma de dosificacion; el envase que la contiene; un proceso para preparar la composicion; y sus usos.
|
WO2012078649A1
(en)
|
2010-12-06 |
2012-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
DK2688557T3
(da)
|
2011-03-23 |
2017-11-27 |
Ironshore Pharmaceuticals & Dev Inc |
Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
AU2012236937B2
(en)
*
|
2011-03-25 |
2017-06-08 |
Selecta Biosciences, Inc. |
Osmotic mediated release synthetic nanocarriers
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CN103458871B
(zh)
|
2011-04-07 |
2015-05-13 |
宝洁公司 |
具有增强的聚丙烯酸酯微胶囊的沉积的调理剂组合物
|
JP6283607B2
(ja)
|
2011-04-07 |
2018-02-21 |
ザ プロクター アンド ギャンブル カンパニー |
ポリアクリレートマイクロカプセルの堆積が増大されたパーソナルクレンジング組成物
|
CN103458858B
(zh)
|
2011-04-07 |
2016-04-27 |
宝洁公司 |
具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
CN109172819A
(zh)
|
2011-07-29 |
2019-01-11 |
西莱克塔生物科技公司 |
产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
|
ES2734221T3
(es)
|
2011-08-08 |
2019-12-04 |
Allergan Pharmaceuticals Int Ltd |
Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
|
WO2013096816A1
(en)
|
2011-12-22 |
2013-06-27 |
Biogen Idec Ma Inc. |
Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
CN102429884A
(zh)
*
|
2011-12-29 |
2012-05-02 |
天津市嵩锐医药科技有限公司 |
盐酸哌甲酯口腔崩解药物组合物
|
EP2852586A1
(de)
|
2012-03-16 |
2015-04-01 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazol-kinaseinhibitoren
|
US9233491B2
(en)
|
2012-05-01 |
2016-01-12 |
Johnson & Johnson Consumer Inc. |
Machine for production of solid dosage forms
|
US9511028B2
(en)
|
2012-05-01 |
2016-12-06 |
Johnson & Johnson Consumer Inc. |
Orally disintegrating tablet
|
US9445971B2
(en)
|
2012-05-01 |
2016-09-20 |
Johnson & Johnson Consumer Inc. |
Method of manufacturing solid dosage form
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
CN104519884A
(zh)
|
2012-06-15 |
2015-04-15 |
公益财团法人先端医疗振兴财团 |
轻度认知障碍的预防和/或治疗剂
|
MX362838B
(es)
|
2012-07-12 |
2019-02-19 |
SpecGx LLC |
Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
|
US10322120B2
(en)
|
2012-07-31 |
2019-06-18 |
Persion Pharmaceuticals Llc |
Treating pain in patients with hepatic impairment
|
US20140161879A1
(en)
*
|
2012-07-31 |
2014-06-12 |
Zogenix, Inc. |
Treating pain in patients with hepatic impairment
|
ES2717469T3
(es)
|
2012-08-15 |
2019-06-21 |
Tris Pharma Inc |
Comprimido masticable de metilfenidato de liberación prolongada
|
US9662313B2
(en)
|
2013-02-28 |
2017-05-30 |
Knopp Biosciences Llc |
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
CA2905131A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US20150366850A1
(en)
|
2013-03-29 |
2015-12-24 |
Wockhardt Limited |
Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
|
US10434194B2
(en)
|
2013-06-20 |
2019-10-08 |
Case Western Reserve University |
PSMA targeted nanobubbles for diagnostic and therapeutic applications
|
US9468630B2
(en)
|
2013-07-12 |
2016-10-18 |
Knopp Biosciences Llc |
Compositions and methods for treating conditions related to increased eosinophils
|
PT3019167T
(pt)
|
2013-07-12 |
2021-03-04 |
Knopp Biosciences Llc |
Tratamento de níveis elevados de eosinófilos e/ou basófilos
|
JP2016537387A
(ja)
|
2013-08-09 |
2016-12-01 |
アラガン ファーマシューティカルズ インターナショナル リミテッド |
経腸投与に適した消化酵素組成物
|
US9642840B2
(en)
|
2013-08-13 |
2017-05-09 |
Knopp Biosciences, Llc |
Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
|
AU2014306597B2
(en)
|
2013-08-13 |
2018-05-17 |
Knopp Biosciences Llc |
Compositions and methods for treating chronic urticaria
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(de)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibitoren des hepatitis-c-virus
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
US10098845B2
(en)
|
2013-10-07 |
2018-10-16 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
WO2015065497A1
(en)
*
|
2013-11-04 |
2015-05-07 |
Schultz Jack William |
Treatment of cognitive, emotional and mental ailments and disorders
|
EP3091966B1
(de)
|
2014-01-10 |
2019-07-31 |
Johnson & Johnson Consumer Inc. |
Verfahren zur herstellung einer tablette mit funkfrequenz und verlustbehafteten beschichteten partikeln
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
MX2016012097A
(es)
|
2014-03-20 |
2017-04-27 |
Capella Therapeutics Inc |
Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
MX2016016907A
(es)
|
2014-06-19 |
2018-04-26 |
Aptalis Pharma Ltd |
Metodo para eliminar contaminantes virales de extractos pancreaticos.
|
KR101686986B1
(ko)
*
|
2014-07-28 |
2016-12-16 |
에스케이케미칼주식회사 |
류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
RU2017106028A
(ru)
|
2014-09-19 |
2018-10-22 |
Дзе Проктер Энд Гэмбл Компани |
Лекарственная форма фенилэфрина с пульсирующим высвобождением
|
CA2902911C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
GB201420306D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Compositions
|
US9956194B2
(en)
|
2014-12-03 |
2018-05-01 |
Velicept Therapeutics, Inc. |
Compositions and methods of using modified release solabegron for lower urinary tract symptoms
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
EA036155B1
(ru)
|
2015-10-16 |
2020-10-06 |
Маринус Фармасьютикалс, Инк. |
Инъекционные составы нейростероида, содержащие наночастицы
|
PT3365321T
(pt)
|
2015-10-23 |
2024-01-12 |
B3Ar Therapeutics Inc |
Zwiterião de solabegron e suas utilizações
|
US20170296476A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Grünenthal GmbH |
Modified release abuse deterrent dosage forms
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
US20170348288A1
(en)
*
|
2016-06-03 |
2017-12-07 |
Velicept Therapeutics, Inc. |
Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
|
EP4233861A3
(de)
|
2016-08-11 |
2023-10-11 |
Ovid Therapeutics, Inc. |
Zusammensetzungen zur behandlung von essentiellem tremor
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
KR20190107655A
(ko)
|
2016-11-01 |
2019-09-20 |
네오스 테라퓨틱스, 엘피 |
Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여
|
US10278930B2
(en)
|
2017-03-16 |
2019-05-07 |
The Procter & Gamble Company |
Method for relieving sinus congestion
|
US10493026B2
(en)
|
2017-03-20 |
2019-12-03 |
Johnson & Johnson Consumer Inc. |
Process for making tablet using radiofrequency and lossy coated particles
|
WO2018172998A1
(en)
*
|
2017-03-23 |
2018-09-27 |
Instituto De Capacitación E Investigación Del Plástico Y Del Caucho |
Dietary supplement derived from natural products by hot melt extrusion (hme) processing
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
US20190381056A1
(en)
|
2018-06-17 |
2019-12-19 |
Axsome Therapeutics, Inc. |
Compositions for delivery of reboxetine
|
US20200147093A1
(en)
|
2018-10-15 |
2020-05-14 |
Axsome Therapeutics, Inc. |
Use of esreboxetine to treat nervous system disorders such as fibromyalgia
|
US11020402B2
(en)
|
2018-10-15 |
2021-06-01 |
Axsome Therapeutics, Inc. |
Use of reboxetine to treat narcolepsy
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020104955A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Dr. Reddy’S Laboratories Limited |
Pharmaceutical compositions of acotiamide and proton pump inhibitor
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
US11324707B2
(en)
|
2019-05-07 |
2022-05-10 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
MX2022001553A
(es)
|
2019-08-05 |
2022-04-18 |
Marinus Pharmaceuticals Inc |
Ganaxolona para su uso en el tratamiento del estado epileptico.
|
CN114828889A
(zh)
|
2019-12-06 |
2022-07-29 |
马瑞纳斯制药公司 |
用于治疗结节性硬化症的加奈索酮
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|